Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Biotechnology

Healthcare
$7.38 -2.78%

-$0.15 today

Market cap
$2.10B
Beta
0.71
P/E (TTM)
-7.1
EPS (TTM)
-$0.71
52W Low $1.99High $5.32

Volume 1.41M

Average 2.42M

MRVI Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $13.41M fell 12.9% year over year, behind the -3.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at +16.6% a year.

Context

  • Depreciation & amortization amounted to 32.6% of revenue in FY2025, up 10.6 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -12.9% toward the trailing-twelve-month pace of -3.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$13.41M+3.3% QoQ
Last fiscal yearDec 2025
$60.47M+6.3% YoY
LTMJun 2026
$56.96M-3.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.9%——
1 year+6.3%——
3-year CAGR+16.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
60.47M USD
Year-over-year change
+6.3%
4-year CAGR
+25.0%

Depreciation & Amortization vs competitors

How MRVI compares with its peers on the latest reported figures

  • MRVI's LTM Jun 2026 depreciation & amortization of $56.96M is the 5th largest of the 9 companies compared; the peer median is $76.63M.
  • Its year-over-year change of -3.2% is the highest of 9, against a peer median of -16.2%.
  • Depreciation & amortization amounts to 27.3% of revenue for MRVI, versus a peer median of 10.1%.
MRVI Competitors Peer median
Depreciation & Amortization for MRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M -23.5%+6.4%4.9%
NEOGNeogen CorporationLTM Aug 2026$117.65M -5.8%+8.7%13.3%
RGENRepligen CorporationLTM Jun 2026$97.31M -7.0%+19.4%12.4%
TECHBio-Techne CorporationLTM Sep 2026$96.75M -8.8%-3.2%7.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$56.96M -3.2%+16.6%27.3%
AZTAAzenta, Inc.LTM Sep 2026$56.52M -7.7%-12.9%9.1%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$17.69M -95.7%+181.5%11.1%
LABStandard BioTools Inc.LTM Mar 2026$10.99M -30.6%-51.5%12.7%
BLFSBioLife Solutions, Inc.LTM Mar 2026$4M -48.5%-34.2%4.0%
Peer median (excluding MRVI) $76.63M-16.2%+1.6%10.1%

Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income469.25M490.66M(119.03M)(259.62M)(130.77M)
Depreciation & Amortization24.75M38.1M48.78M56.87M60.47M
Deferred Income Tax46.9M42.32M754.94M2.32M(20K)
Stock-Based Compensation10.46M18.67M34.59M49.42M0
Change in Working Capital(176.63M)(45.08M)97.84M(12.61M)(7.98M)
Accounts Receivables(70.39M)(22.27M)84.4M14.36M12.82M
Inventory(21.57M)9.46M649K377K8M
Accounts Payables676K(1.58M)5.28M723K(7.35M)
Other Working Capital(85.34M)(30.69M)7.52M(28.07M)(21.45M)
Other Non-Cash Items(6.16M)(8.7M)(690.9M)171.1M20.73M
Operating Cash Flow368.57M535.98M126.22M7.47M(57.57M)
Capital Expenditures(14.85M)(17.09M)(65.55M)(29.66M)(13.15M)
Acquisitions (Net)119.96M(238.35M)(69.62M)0(18.26M)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities548K(12.17M)12.87M5.34M0
Investing Cash Flow105.66M(267.61M)(122.31M)(24.32M)(31.41M)
Debt Repayment(6M)(5.44M)(5.77M)(234.07M)(5.44M)
Common Stock Issued1.71M2.36M000
Common Stock Repurchased00(20K)(2.08M)0
Dividends Paid00000
Other Financing Activities(154.76M)(184.42M)(55.3M)443K(11.06M)
Financing Cash Flow(159.05M)(187.5M)(61.09M)(235.71M)(16.5M)
Effect of Forex Changes(88K)000(32K)
Net Change in Cash315.09M80.87M(57.18M)(252.56M)(105.51M)
Free Cash Flow353.72M518.89M60.67M(22.19M)(70.72M)

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Intrinsic Alpha fair value

Locked

Current Price

$7.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.